TrialThe Lancet. Haematology2025

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.

Roberto Mina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.